Analysts Have Made A Financial Statement On Capillary Technologies India Limited's (NSE:CAPILLARY) First-Quarter Report

Shareholders of Capillary Technologies India Limited (NSE:CAPILLARY) will be pleased this week, given that the stock price is up 13% to ₹581 following its latest first-quarter results. It was a workmanlike result, with revenues of ₹2.6b coming in 4.6% ahead of expectations, and statutory earnings per share of ₹6.87, in line with analyst appraisals. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the consensus forecast from Capillary Technologies India's two analysts is for revenues of ₹10.8b in 2027. This reflects a major 34% improvement in revenue compared to the last 12 months. Per-share earnings are expected to bounce 38% to ₹7.30. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹10.8b and earnings per share (EPS) of ₹11.80 in 2027. So there's definitely been a decline in sentiment after the latest results, noting the pretty serious reduction to new EPS forecasts.

Check out our latest analysis for Capillary Technologies India

The consensus price target held steady at ₹643, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Capillary Technologies India's rate of growth is expected to accelerate meaningfully, with the forecast 47% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 28% over the past year. Compare this with other companies in the same industry, which are forecast to grow their revenue 11% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Capillary Technologies India to grow faster than the wider industry.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Capillary Technologies India. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Capillary Technologies India. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2029, which can be seen for free on our platform here.

We also provide an overview of the Capillary Technologies India Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.